Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Core Viewpoint - Medicus Pharma Ltd. has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) for Doxorubicin Microneedle Array (D-MNA) aimed at non-invasive treatment of basal cell carcinoma (BCC) of the skin [1]. Group 1 - The expansion of the clinical study into the UK is intended to enhance global patient recruitment and clinical dataset for a pivotal study program [1]. - The focus of the study is on evaluating a novel therapeutic asset, D-MNA, which represents a potentially disruptive approach in the treatment of BCC [1].